Document is current
Any future updates will be listed below
-
Authors
Mirandola, Leonardo
Chiriva-Internati, Maurizio
Bresalier, Robert
Marincola, Francesco M.
Figueroa, Jose A.
Dahlbeck, Scott
- License Information
-
More Information
Article History
Received: 10 July 2019
Accepted: 25 October 2019
First Online: 17 November 2019
Ethics approval and consent to participate
: The safety, immunogenicity, and clinical activity of BSK01™ were evaluated in a Phase I clinical trial (ExternalRef removed Identifier: NCT02705703). Patients were enrolled upon signing informed consent per IRB specifications (Salus central IRB, ExternalRef removed).
: Not applicable.
: The authors declare that they have no competing interests.
